Although it has been three weeks, Liang Huiqing, general manager of Foshan Anpuze Biomedical Co., Ltd. (hereinafter referred to as "Anpuze"), still clearly remembers that she left the Zhejiang Medical Investment Promotion Conference that night and flew back to Guangzhou. The next morning she drove to Nanhai for ATTP Certification Series Training for International Registered Technical Managers. Class scene.

         This is the first time that the International Registered Technical Managers Training Course has been held in Guangdong. As a Sino-British cooperative training course, it will focus on R&D and innovation of cutting-edge technologies, financing risks of start-ups and business operation modes in the next three months. "I missed the training in the past few days because I took the project to Zhejiang to participate in the road show. My colleagues present shared the dry goods of the training course with me every day. Before returning to Guangdong, I decided to get off the plane and rush to the scene directly." Liang Huiqing said.

          At present, South China Sea is making great efforts to promote the construction of "National Robot Integrated Innovation Center", "Global Creator New City", "Global Product Cross-Border Innovation Center" three major projects, and hopes to take this opportunity to undertake more high-end superior resources. "This training is a good entry point to introduce international high-end resources." According to Li Xiaojia, Standing Committee of the South China Sea Regional Committee, local enterprises can judge the commercial value of technological achievements by learning international standards and advanced experience, and accelerate the process of industrialization and enterprise transformation and upgrading. It can also promote the internationalization and high-end development of innovation resources in the South China Sea, and accelerate the introduction of a complete system of international technology transfer.

        A "Training Teachers'Experience Sharing is so Similar to Our Experience"Before the end of the first training course, Liang Huiqing, who arrived at the scene, joined his colleague Peng Wendan and took notes while listening to the class. "The experience of technology transfer abroad shared by teachers is very similar to our experience." Liang Huiqing said.

      At the end of July this year, the first project variety of ampezer (national class II new drug, monoclonal antibody) successfully passed the application for approval of clinical trials, which is also the first approval of clinical trials of monoclonal antibodies in Foshan. As early as five years ago, Ampser formally signed a transfer contract, took the project from the US Biopharmaceutical Technology Development Team, and carried out incubation research and development in the South China Sea Biopharmaceutical Industry Base of the Chinese Academy of Sciences. "At present, the project has a Preliminary Valuation of 100 million yuan, and we have five invitations at the road show."

        Until now, Liang Huiqing still clearly remembers the "game" process of international technology transfer. In her opinion, the most important thing in this process is to judge whether the fitted project is trustworthy. "As long as a slight misjudgment, it may lead to long-term research and development results directly drift away." She said that, especially in the field of biomedicine, due to the long-term R&D investment and personnel capital arrangement adjustment, the requirements for collaborators and project screening are also more stringent to a large extent.

        "Teachers in class give examples to show that both sides of technology transfer have different understandings about the definition of project milestones, so it is necessary to discuss the definition and write it into the contract text." Liang Huiqing said that on the other hand, by introducing professional third-party organizations to complete the evaluation work, it also ensures the fluency and compliance of the future development of the project to a certain extent. "This is what we need to pay more attention to in future projects."

        Nowadays, as one of the first enterprises to enter the Guangdong Biomedical Industry Base of Foshan High-tech Zone, Anpuze has built the first platform for research and development and pilot test of biomacromolecule drugs in Foshan. With the development of clinical trials, this biomedical enterprise is ushering in a huge market space.

     "We are actively negotiating with Canada on a new project for nanobiosensors, and have completed preliminary intellectual property rights analysis." Liang Huiqing said that after listening to the first ATTP training course, I think international technology transfer needs to be treated with more caution. For example, the degree of technology completeness, risk assessment and technology transfer methods need to be carefully considered and discussed.